TARGETING CHEMOTHERAPY USING ANTIBODY-COMBINED LIPOSOME AGAINST HUMAN PANCREATIC-CANCER CELL-LINE

Anti-tumor effect of Adriamycin (ADM)-encapsulated and CA19-9 antibody-conjugated artificial lipid membrane follicle liposomes against a human pancreatic cancer cell-line PK-1 was studied in vitro and in vivo. The liposome compound (lipo (c) over bar ADM=Ab) showed a stronger cell damage than ADM-encapsulated liposome (lipo (c) over bar ADM) and free ADM, especially when the contact time was short and the concentration was low. The intra-tumor concentration of ADM in the group of i.v. injection of lipo (c) over bar ADM=Ab showed the highest value, over twice those of lipo (c) over bar ADM and free ADM after 120 hr. Lipo (c) over bar ADM=Ab showed a significant inhibitory effect on the tumor growth inhibition test in vivo, and the final tumor weight at the 19th day was 27% in the group of lipo (c) over bar ADM=Ab and 52% in the group of free BDM as compared with the control. The targeting chemotherapy using liposomes was demonstrated to have a stronger anti-tumor effect than the administration of anti-cancer drug alone owing to enhanced tumor accessibilty and good targeting.